15 Nov 2026
Clascoterone for Hair Loss: Approval, Evidence, Safety, and Availability
Understand clascoterone’s FDA status, hair-loss evidence, safety, and availability so you can weigh treatment options. Review the facts before deciding.
Share
TL;DR
Clascoterone is a topical androgen-receptor inhibitor. Winlevi cream 1%, which contains clascoterone, is FDA approved for acne vulgaris in patients aged 12 and older. The sources reviewed for this article do not document FDA approval of clascoterone for hair loss as of October 30, 2026.
That distinction matters. An approved acne cream is not interchangeable with an investigational scalp formulation, even when both contain the same active ingredient. Before considering any topical anti-androgen for hair loss, we recommend confirming the diagnosis and reviewing the exact formulation, evidence, risks, cost, and treatment burden.
Table of Contents
- What Is Clascoterone—and Is It Approved for Hair Loss?
- Clascoterone, Winlevi, Breezula, and NOLUVA: What Each Name Means
- Why Acne Approval Does Not Prove Hair Regrowth
- What Hair-Loss Trials Can—and Cannot—Tell Us About Clascoterone
- Clascoterone Side Effects: Why Topical Does Not Mean Risk-Free
- Can You Buy Clascoterone for Hair Loss—or Take It as a Tablet?
- Clascoterone vs Finasteride and Minoxidil: Different Roles, Not Interchangeable Drugs
- Before Chasing Clascoterone, Confirm What Is Causing Your Hair Loss
- FAQ
- Start With the Cause, Not the Headline
What Is Clascoterone—and Is It Approved for Hair Loss?

Clascoterone is a topical androgen-receptor inhibitor. It is designed to interfere with androgen signalling in the tissue where it is applied.
Winlevi cream 1% is a prescription clascoterone product approved by the FDA for acne vulgaris in patients aged 12 and older. The source material reviewed for this article documents that acne indication but does not establish an FDA-approved use for hair loss.
This is why the phrase “FDA-approved clascoterone” needs context. It accurately describes Winlevi for its approved acne indication. It does not mean every concentration, formulation, application site, or proposed use of clascoterone has been approved.
Clascoterone competes with androgens, particularly dihydrotestosterone, or DHT, for androgen-receptor binding. This limits downstream signalling involved in acne. Because androgen signalling is also relevant to androgenetic alopecia, researchers have explored whether local receptor blockade could benefit the scalp.
The rationale is plausible, but a plausible mechanism is not proof of hair regrowth.
Hair-loss evidence must relate to the scalp product being evaluated: its concentration, vehicle, dose, application schedule, treatment duration, and intended population. Evidence for an acne cream cannot answer all those questions.
Regulatory status can change. The information here was reviewed on October 30, 2026. Our clascoterone scalp-trial update should be read alongside current FDA records and official developer announcements.
The short answer on approval
Winlevi is a prescription cream containing clascoterone 1%, equivalent to 10 milligrams per gram. It is FDA approved for the topical treatment of acne vulgaris in patients aged 12 and older.
That approval does not establish clascoterone as an approved hair-loss treatment. Several regulatory terms are often confused:
- Investigational: A product or use is being studied and has not been approved for that purpose.
- Off-label: A licensed clinician prescribes an approved product for a use outside its approved labelling.
- Submitted for review: A regulator is assessing an application, but no approval decision has been issued.
- Approved: A regulator has authorised a specific product, formulation, population, indication, and label.
A clinical trial, company announcement, development name, online listing, or off-label prescription does not itself amount to approval.
The accurate summary is straightforward: Winlevi cream 1% is FDA approved for acne vulgaris, but that approval does not establish clascoterone as an approved treatment for hair loss.
How a topical anti-androgen is intended to work
Androgens bind to receptors and trigger cellular activity. Clascoterone competes for those receptors, potentially reducing androgen signalling in treated tissue.
In acne, published research describes effects on androgen-regulated lipid production and inflammatory pathways. In androgenetic alopecia, the proposed aim is to reduce signalling associated with progressive follicle miniaturisation.
Blocking a pathway does not guarantee a visible result. A hair follicle affected by long-standing miniaturisation may not necessarily produce a thicker or cosmetically meaningful hair. Controlled studies must show that the exact scalp formulation improves relevant outcomes.
Topical delivery may limit systemic exposure compared with some oral treatments, but it does not guarantee that a drug remains entirely within the skin. Exposure can be affected by:
- Concentration and quantity
- Treatment-area size
- Vehicle or formulation
- Application frequency
- Skin inflammation or barrier damage
- Other products used on the same area
Mechanism explains why a treatment might work. Clinical evidence tells us whether it does.
Clascoterone, Winlevi, Breezula, and NOLUVA: What Each Name Means
Clascoterone, Winlevi, Breezula, and NOLUVA may appear together in coverage of acne and hair-loss research. They should not be treated as four unrelated drugs, but they also should not be assumed to be interchangeable products.
| Name | What it refers to | Practical meaning |
|---|---|---|
| Clascoterone | The active pharmaceutical ingredient | The ingredient name alone does not identify a concentration, vehicle, dose, or approved use |
| Winlevi | A commercial prescription brand | Clascoterone cream 1%, FDA approved for acne vulgaris in patients aged 12 and older |
| Breezula | A name associated with clascoterone hair-loss development | It should be assessed through current trial, developer, and regulatory records rather than equated with Winlevi |
| NOLUVA | A name appearing in hair-loss development coverage | A development or proposed brand name does not establish approval or availability |
Product names and development programmes can change. When we assess any reference to Breezula or NOLUVA, we look for the current developer, exact formulation, clinical-trial registration, regulatory status, and final product label, if one exists.
Active ingredient versus product name
Clascoterone is the active ingredient. Winlevi is a specific prescription product with a 1% concentration, cream vehicle, approved indication, and product label.
A shared ingredient does not make different products substitutable. Researchers may change the:
- Concentration
- Vehicle
- Quantity applied
- Application site
- Dosing frequency
- Treated surface area
- Intended population
Each change can affect delivery, tolerability, systemic exposure, and efficacy. “Contains clascoterone” is therefore not a complete product description.
Why concentration, vehicle, dose, and application site matter
Concentration describes the proportion of active ingredient in a formulation. Dose also depends on how much product is applied, how often it is used, and how large an area it covers.
Two products with the same concentration may deliver different total amounts. Products with different concentrations may also produce different exposure depending on application and absorption.
The vehicle matters just as much. A facial cream may spread, dry, penetrate, and leave residue differently from a scalp-oriented preparation. Hair can make application harder because the product needs to reach the scalp rather than coat the strands.
Facial acne treatment and long-term scalp treatment also create different practical demands. The scalp may require broader coverage, while greasiness, residue, drying time, and styling disruption can affect adherence.
These are not minor packaging differences. They help determine whether a treatment can work safely and consistently.
Why Acne Approval Does Not Prove Hair Regrowth

Evidence supporting Winlevi for acne supports that approved indication. It does not support a general claim that any clascoterone product grows hair.
Acne studies and hair-loss studies measure different outcomes. Acne research may examine inflammatory lesions, non-inflammatory lesions, and investigator-assessed treatment success. Hair-loss research may assess target-area hair counts, hair width, visible coverage, standardised photographs, and patient-reported improvement.
Different conditions require different evidence.
What Winlevi was approved to treat
Winlevi cream 1% is approved for acne vulgaris in patients aged 12 and older. Published literature describes clascoterone as competing with androgens, especially DHT, at androgen receptors and limiting signalling involved in acne.
That evidence applies to the studied product, population, dose, and application conditions. It does not establish:
- How much cream should be used on a thinning scalp
- Whether the cream reaches affected follicles effectively
- How long scalp treatment should continue
- Whether a larger application area changes exposure
- Whether the vehicle is practical for regular scalp use
Acne instructions should not be converted into do-it-yourself scalp directions. The acne label was not designed to answer hair-loss dosing or efficacy questions.
What dedicated hair-loss evidence must establish
A credible hair-loss programme should compare the active product with an appropriate control, often the same vehicle without the active ingredient. It should also show whether any measured difference is large enough to matter to patients.
Useful outcomes include:
- Target-area hair counts
- Hair thickness or diameter
- Standardised photographic assessments
- Patient satisfaction and perceived improvement
- Scalp reactions and treatment discontinuations
- Systemic exposure under the proposed regimen
- Durability of any benefit
- Outcomes after treatment stops
Results must also be interpreted according to the enrolled population. Findings from adults with a defined degree of androgenetic alopecia may not apply to adolescents, advanced follicle loss, scarring alopecia, alopecia areata, or shedding caused by illness.
What Hair-Loss Trials Can—and Cannot—Tell Us About Clascoterone
Last reviewed: October 30, 2026. The sources reviewed here discuss clinical development of clascoterone for hair loss but do not provide the complete evidence and regulatory documentation needed to treat it as an approved scalp therapy.
Development coverage has referred to phased clinical testing, including later-stage research. However, the supplied material does not present a complete peer-reviewed record of protocols, absolute endpoint results, confidence intervals, subgroup findings, and long-term safety outcomes.
A topline company announcement can indicate whether a selected endpoint was met. It is not equivalent to a full publication, independent review, regulatory assessment, or approval.
How to read the study population and design
Start by checking who participated. Male and female pattern hair loss can differ in presentation, hormonal context, severity grading, and permitted background treatment.
Then examine the trial design:
- Randomisation: Participants are assigned to groups by chance to reduce selection bias.
- Blinding: Participants, investigators, or both do not know who receives active treatment.
- Vehicle control: The control group receives the same base formulation without clascoterone.
- Treatment duration: Hair changes slowly, so short studies may miss delayed benefits or longer-term risks.
- Eligibility criteria: Narrow criteria can limit how well the findings apply to people with mixed or uncertain diagnoses.
A useful report should identify the trial phase, participant population, diagnosis, severity, formulation, concentration, application schedule, duration, comparator, primary endpoint, and major exclusions.
Without those details, a headline cannot support a personal treatment decision.
Hair counts, photographs, and patient-reported outcomes
Target-area hair counts measure hairs within a defined section of scalp. This creates a consistent research endpoint, but it does not automatically equal improved whole-scalp coverage.
When a result is reported as a percentage, we also want to know:
- Baseline counts in each group
- Absolute changes from baseline
- The vehicle-group response
- The size of the measured area
- Confidence intervals
- Discontinuation rates
- The proportion with visible improvement
- Whether standardised photographs supported the count
- Whether participants noticed a worthwhile difference
Relative changes may sound impressive even when the absolute difference is small. Statistical significance also does not mean that every participant improved or that the result was cosmetically meaningful.
The strongest case usually combines objective measurements with blinded photographic review and patient-reported improvement.
Evidence limitations and unanswered questions
Several questions matter before we can judge a long-term hair-loss treatment:
- Are complete results available in a peer-reviewed publication?
- Were findings consistent across sites and severity groups?
- Did age, sex, baseline density, or hair type affect the result?
- How many participants stopped because of irritation or inconvenience?
- Did improvement continue, plateau, or decline?
- What happened after discontinuation?
- How did the product compare directly with established treatments?
- Was systemic exposure adequately assessed?
Trial conditions can also be more supportive than ordinary use. Participants may receive reminders, monitoring, free study products, and detailed application training. Real-world adherence may be lower, particularly when a product must be distributed across hair-bearing skin.
Even positive late-stage results do not authorise sale for an indication. Regulatory review remains a separate step, and any eventual label may differ from the original development plan.
Clascoterone Side Effects: Why Topical Does Not Mean Risk-Free
Safety information for Winlevi acne use should be separated from the evidence for any scalp formulation. Concentration, vehicle, dose, treatment area, and duration may all affect the safety profile.
Published acne literature describes adverse effects as generally mild, infrequent, and mainly local under the conditions studied. Long-term acne research cited in the source material did not identify systemic anti-androgenic effects such as reduced libido or feminisation in male participants. Those findings should not be extended automatically to a different scalp product or regimen.
Our guide to pre-treatment risk screening for topical and oral hair-loss treatments explains why the route of administration is only one part of a safety assessment.
Local reactions and scalp tolerability
Topical products may cause local reactions such as:
- Redness
- Dryness
- Scaling
- Itching
- Burning or stinging
- General irritation
Tolerability depends partly on the vehicle, amount, frequency, skin condition, and other products used. Styling products, medicated shampoos, retinoids, exfoliating ingredients, and alcohol-based solutions may add to irritation.
Broken, infected, inflamed, or sunburned skin can respond differently from intact skin. Pain, marked inflammation, or signs of infection warrant clinical assessment rather than experimentation.
Practical burden matters too. A product that leaves residue, interferes with styling, or is hard to spread may be used inconsistently. Some people may also apply too much in an attempt to compensate, creating additional uncertainty about exposure.
Systemic findings and monitoring questions
Topical treatment does not necessarily mean zero systemic exposure. The amount absorbed may differ between people and formulations.
We recommend product-specific medical guidance when factors such as these apply:
- Pregnancy or plans for pregnancy
- Lactation
- Treatment of children or adolescents
- Endocrine concerns
- Large treatment areas
- Damaged skin barriers
- Multiple topical products
- Other prescription treatments
Safety decisions should follow the current label for an approved product or the formal protocol for a clinical trial. They should not be based only on the active ingredient’s name.
What remains unknown for long-term hair-loss use
Pattern hair loss is chronic. If a treatment works only while it is used, people may need to continue for years. A shorter controlled study cannot answer every question about prolonged exposure.
Ordinary use may also differ from trial use. People miss applications, combine products, use larger quantities, or continue despite irritation. Rare adverse events are difficult to identify in small or short studies.
Longer observation, larger populations, regulatory review, and postmarketing monitoring—if a product is approved—help build a clearer safety picture.
Can You Buy Clascoterone for Hair Loss—or Take It as a Tablet?
Winlevi may be prescribed for acne, but that does not establish the availability of an FDA-approved clascoterone hair-loss product. An online listing is not proof of approval, authenticity, quality, or suitability.
The sources reviewed here also do not document an FDA-approved clascoterone tablet for hair loss. The established acne product and the hair-loss development discussed in the source material are topical.
Approved product, off-label use, compounded product, or unverified listing?
An offer for “clascoterone for hair growth” could describe very different products:
| Category | What it means | What to verify |
|---|---|---|
| Approved acne product | Winlevi cream 1% prescribed for acne | Label, prescriber, pharmacy, and intended use |
| Off-label prescription | An approved product prescribed outside its label | Clinical rationale, evidence limits, dose, and monitoring |
| Compounded preparation | A pharmacy-prepared product made for an individual prescription | Pharmacy licence, concentration, ingredient source, and beyond-use information |
| Investigational product | A defined formulation used in authorised research | Trial registration, consent process, eligibility, and oversight |
| Unverified listing | A product with uncertain identity or quality | Avoid relying on marketing claims or an ingredient name alone |
Red flags include a missing concentration, unclear manufacturer or pharmacy, no verifiable ingredient list, absent lot information, and claims that a product is “the same as” a clinical-trial formulation.
Why using acne cream on the scalp is not a do-it-yourself substitute
Winlevi’s cream vehicle and 1% concentration may differ from formulations studied for the scalp. Applying acne cream across thinning areas may also involve a different surface area and total amount.
The cream may be difficult to distribute through hair or may leave unwanted residue. More product does not resolve uncertainty about follicular delivery, effectiveness, or systemic exposure.
No scalp instructions should be inferred from the acne label. Off-label prescribing is a clinical decision, not a do-it-yourself shortcut from acne approval to hair-loss treatment.
Clascoterone vs Finasteride and Minoxidil: Different Roles, Not Interchangeable Drugs
Clascoterone is not simply topical finasteride, nor is it another form of minoxidil. These treatments differ in mechanism, evidence, formulation, regulatory status, and safety considerations.
| Feature | Clascoterone for hair loss | Finasteride | Minoxidil |
|---|---|---|---|
| Core rationale | Blocks androgen receptors in treated tissue | Reduces DHT formation by inhibiting 5-alpha-reductase | Supports hair growth through a non-anti-androgen pathway |
| Evidence position | Formulation-specific clinical development | Established evidence for defined products and populations | Established evidence for defined products and populations |
| Route | Proposed topical scalp use | Commonly oral; topical preparations require separate evaluation | Commonly topical; oral use has different risks and status |
| Practical burden | Coverage, residue, frequency, and long-term adherence | Regular dosing and appropriate clinical review | Regular application, drying time, residue, and continued use |
| Safety principle | Topical does not mean no systemic exposure | Systemic and reproductive considerations require review | Risks depend on route, dose, and individual health |
No treatment is best for everyone. We focus on whether an option fits the diagnosis, medical history, goals, and ability to follow the regimen.
Clascoterone versus finasteride
Clascoterone is intended to block androgen receptors where it is applied. Finasteride works earlier in the pathway by inhibiting an enzyme that converts testosterone to DHT.
They are distinct interventions. Claims that clascoterone is “finasteride without the side effects” are unsupported because they assume comparable hair-growth efficacy while dismissing unresolved product-specific risks.
Route matters, but so do eligibility, reproductive considerations, other medicines, health history, and monitoring needs.
Clascoterone versus minoxidil
Minoxidil does not work by blocking androgen receptors. It has an established role in hair-loss care through defined formulations and populations.
Any comparison should specify the product, route, concentration, population, diagnosis, schedule, and endpoint. A broad “clascoterone versus minoxidil” claim leaves out too much information to be useful.
Both topical approaches may require consistent, long-term application. Drying time, residue, scalp comfort, and styling compatibility therefore affect real-world results.
Different mechanisms could potentially appear in a broader treatment plan, but theoretical compatibility is not proof that a particular combination is effective or safe.
Questions that matter more than novelty
Before prioritising a new ingredient, we ask:
- Is the diagnosis androgenetic alopecia?
- How advanced is follicle miniaturisation?
- What outcome is realistic?
- Which treatments have evidence for this population?
- Which risks matter for the person’s medical history?
- Can the regimen be followed consistently?
- How will progress be measured?
Our resource for comparing online hair-loss plans by ingredient fit helps distinguish familiar ingredient names from the evidence and practical trade-offs behind them.
Before Chasing Clascoterone, Confirm What Is Causing Your Hair Loss
Androgenetic alopecia involves progressive, patterned follicle miniaturisation influenced by genetic and androgen-related factors. It may appear as temple recession, crown thinning, a widening part, or reduced density in a recognisable pattern.
Not every receding hairline or period of shedding is androgenetic alopecia. Using an anti-androgen for the wrong condition may waste time and delay appropriate care.
At Roots by GA, we take a diagnosis-first view. Personalisation should start with the likely cause and clinical context, not the newest investigational ingredient.
Pattern hair loss versus other causes of shedding
Different presentations can point towards different causes:
- Sudden diffuse shedding: May be consistent with telogen effluvium after illness, surgery, major stress, rapid weight change, or another physiological trigger.
- Smooth, sharply defined patches: Can suggest alopecia areata and warrant clinical assessment.
- Pain, burning, inflammation, heavy scaling, or scarring: Needs prompt evaluation because some inflammatory or scarring disorders can cause permanent damage.
- Breakage near areas of tension: May indicate traction or damaging hair practices.
- General thinning with other symptoms: Medicines, thyroid disorders, nutritional problems, or systemic illness may need investigation.
Causes can overlap. Someone with androgenetic alopecia may also experience temporary shedding after illness, making the change appear unusually rapid.
What a personalised assessment should consider
A useful assessment looks beyond product preference. We consider:
- Pattern and location of thinning
- Age at onset and rate of progression
- Family history
- Recent illness or physiological stress
- Medical conditions
- Prescription drugs and supplements
- Nutrition and weight changes
- Scalp symptoms
- Previous treatments, adherence, and response
Genetic information may add context about predisposition, but it cannot replace clinical evaluation or exclude other causes.
Baseline photographs are also useful. Consistent lighting, distance, hairstyle, angle, and scalp position make progress easier to assess without mistaking normal visual variation for change.
A science-led next step
A diagnosis-first assessment can clarify whether a pattern is consistent with androgenetic alopecia and which established options fit the person’s history and preferences. Progress can then be measured against a reliable baseline.
Roots by GA does not present clascoterone as a currently supplied or recommended hair-loss product. We monitor developing evidence while keeping our treatment discussions grounded in diagnosis, individual risk, and established options.
FAQ
Last reviewed: October 30, 2026.
Is clascoterone good?
That depends on the condition, product, evidence, risks, and treatment goals. Winlevi cream 1% has an FDA-approved role in acne vulgaris. Its acne approval should not be treated as proof that a different clascoterone formulation will regrow hair.
Does clascoterone work for acne?
Winlevi cream 1% demonstrated efficacy in the research supporting its FDA approval for acne vulgaris in patients aged 12 and older. Individual responses vary, and use should follow current prescribing information. Acne results do not provide evidence or dosing instructions for scalp hair growth.
Is clascoterone FDA approved for hair loss?
The sources reviewed for this article document FDA approval of Winlevi cream 1% for acne, not clascoterone for hair loss. Because regulatory status can change, we recommend checking current FDA records and official product information.
Is there a clascoterone tablet?
The reviewed sources do not document an FDA-approved clascoterone tablet for hair loss. The established acne product and the hair-loss development discussed here involve topical formulations. Online references to tablets should not be treated as proof of approval, authenticity, or safety.
Should I buy clascoterone online for hair growth?
We do not recommend buying an unverified or improperly prescribed product. Confirm the diagnosis, product identity, concentration, manufacturer or compounding pharmacy, ingredient source, evidence, and clinical oversight first.
Start With the Cause, Not the Headline
Clascoterone is scientifically interesting, but novelty should not outrank diagnosis. Start a personalised, diagnosis-first assessment with Roots by GA to identify what may be driving the hair loss and discuss treatment options based on evidence, risk, and individual fit.
Roots by Genetic Arts
15 Nov 2026
Thanks for your order!
Login into your profile to set up your account.